143 related articles for article (PubMed ID: 37305390)
21. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
Jiang Y; Zhang C; Zhang J; Han D; Shi X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
23. Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
Sun S; Deng M; Wen J; Chen X; Xu J; Liu Y; Wan H; Wang J; Yan L; He Y; Xu Y
BMC Cancer; 2023 Mar; 23(1):292. PubMed ID: 37004045
[TBL] [Abstract][Full Text] [Related]
24. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
[TBL] [Abstract][Full Text] [Related]
25. Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.
Chen X; Zhang T; Zhai X; Wan Z; Ge M; Liu C; Tan M; Xu D
Front Immunol; 2022; 13():1037808. PubMed ID: 36405755
[TBL] [Abstract][Full Text] [Related]
26. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
27. DNA damage repair-related gene signature predicts prognosis and indicates immune cell infiltration landscape in skin cutaneous melanoma.
Liang L; Mai S; Mai G; Chen Y; Liu L
Front Endocrinol (Lausanne); 2022; 13():882431. PubMed ID: 35957812
[TBL] [Abstract][Full Text] [Related]
28. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
30. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM.
Zhang W; Xie X; Huang Z; Zhong X; Liu Y; Cheong KL; Zhou J; Tang S
Front Immunol; 2022; 13():919145. PubMed ID: 36211371
[TBL] [Abstract][Full Text] [Related]
31. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
32. Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma.
Tian J; Cao ZJ; Zhang Y; Zhou JK; Yang L
Heliyon; 2023 May; 9(5):e16153. PubMed ID: 37215879
[TBL] [Abstract][Full Text] [Related]
33. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
35. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
37. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
38. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
39. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
40. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Liu X; Wang J
Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
